Patents Examined by Jean Cornet
  • Patent number: 9944619
    Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 17, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Randall L. Halcomb, Yunfeng Eric Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Patent number: 9931341
    Abstract: The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: April 3, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSITANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT-PARIS 7, IMAGINE
    Inventors: Laurence Legeai-Mallet, Arnold Munnich, Patricia Busca, Florent Barbault
  • Patent number: 9877935
    Abstract: The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: January 30, 2018
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Thummar Rakesh, Pawar Shantaram, Kane Prashant, Bhowmick Subhas Balaram, Kumar Samarth, Thakkar Milan Natvarbhai, Dave Kandarp Maheshkumar
  • Patent number: 9844547
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: December 19, 2017
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9795132
    Abstract: A disinfecting shower cleaner composition including a medium-chain fatty acid coupled with a nonionic surfactant providing temperature stable antimicrobial compositions. The invention specifically relates to antimicrobial compositions including fatty acid antimicrobial agents coupled with an ethoxylated amine and methods of using the antimicrobial compositions.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 24, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Elizabeth Kiesel, Michael Edward Besse, Lisa A. Hellickson, Mark Levitt, Daniel E. Pedersen
  • Patent number: 9789171
    Abstract: This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: October 17, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Mark C. Poznansky, John T. Potts, Jr., Fabrizio Vianello, Natalia Papeta
  • Patent number: 9782400
    Abstract: A compound suitable for treating cancer, in particular NSCLC, inhibits activity of oncogenic ROS1 kinase and ALK kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety. The presence of the structural components allows for an advantageous interaction with the ROS1 kinase domain and, further, with the ALK kinase domain. Hence, said compound represents a highly promising opportunity for patients bearing ROS1- or ALK-dependent cancer. A composition, in particular a pharmaceutical composition, includes the compound. A method for targeting cancer cells harboring an abnormality in ROS1 gene or ALK gene includes contacting a cell with the compound.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: October 10, 2017
    Assignee: Macau University of Science and Technology
    Inventors: Xiao Jun Yao, Lai Han Leung, Lian Xiang Luo, Liang Liu
  • Patent number: 9771379
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 26, 2017
    Assignee: PFIZER INC.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill
  • Patent number: 9763948
    Abstract: Optionally substituted (1- or 3-oxy)-4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or (1- or 3-oxy)-4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: September 19, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Jun Zhao
  • Patent number: 9763962
    Abstract: An injectable preparation of estrogenic and progestrogenic hormonal compounds in an anhydrous excipient injected to synchronize estrus in non-menstruating placental female animals, and a five to nine day protocol to apply the unique preparation to achieve estrus synchronization.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 19, 2017
    Inventors: Jennifer Yoakum, Hal Witt
  • Patent number: 9763439
    Abstract: The invention proposes a container further extending the shelf life of foods, particularly berries, by including an active agent having antifungal capability into the container surface so that when the fruit is packaged inside the container it is permanently exerted an antifungal effect over the surface, which is the place on the longer determinants occurs, but also contributing to preserve the general environment. Also it proposes a preparation process and its use.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: September 19, 2017
    Assignee: Universidad de Santiago de Chile
    Inventors: Maria Paula Junqueira Conceicao Gonsalves, Andrea Marcarena Tapia Ulloa
  • Patent number: 9758512
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: September 12, 2017
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
  • Patent number: 9751838
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: September 5, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paul Sabatier Toulouse III, Universite Paris-Sud, Universite d'Orleans
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • Patent number: 9750813
    Abstract: The present disclosure refers to heptyl glucoside included, as a natural solubilizer and as a skin penetration enhancer, in transdermal pharmaceutical compositions. Heptyl glucoside is a natural alkyl glycoside and a hydrotrope that improves solubility of active pharmaceutical ingredients (APIs), thereby enhancing skin permeability to APIs. Transdermal pharmaceutical compositions including heptyl glucoside allow lower APIs dosage requirements. Heptyl glucoside can be combined with at least one API and suitable ingredients to formulate transdermal pharmaceutical compositions with improved skin permeability, thereby promoting percutaneous absorption of APIs. Transdermal pharmaceutical compositions including heptyl glucoside can be formulated in a plurality of dosage forms, such as, a liquid, cream, paste, gel, lotion, patch (e.g., matrix and reservoir), tape, film former (e.g., plaster), and the like.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: September 5, 2017
    Assignee: Professional Compounding Centers of America (PCCA)
    Inventor: Daniel Banov
  • Patent number: 9750726
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 5, 2017
    Assignee: Glaxo Group Limited
    Inventors: Darrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
  • Patent number: 9730921
    Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: Duke University
    Inventors: Soman N. Abraham, Ashley L. St. John
  • Patent number: 9718819
    Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 1, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth L. Arrington, Christopher Burgey, Robert Gilfillan, Yongxin Han, Mehul Patel, Chun Sing Li, Yunfu Luo, Zhiyu Lei
  • Patent number: 9708329
    Abstract: The present invention relates to a selective dual delta (?) and gamma (?) PI3K protein kinase modulator (S)—N-(5-(4-amino-1-(1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-4H-chromen-2-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl) methane sulfonamide, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of PI3K kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 18, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Prashant K. Bhavar, Swaroop K. Vakkalanka
  • Patent number: 9708347
    Abstract: Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 18, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim
  • Patent number: 9707296
    Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 18, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masazumi Kojima, Yoshio Kuno, Hiroaki Nakagami, Shinji Sagasaki, Koichi Ishidoh, Gaku Sekiguchi